首页|miRNA在糖尿病性视网膜病变中的最新研究进展

miRNA在糖尿病性视网膜病变中的最新研究进展

Recent research progress of miRNA in diabete retinopathy

扫码查看
原文链接
  • 万方数据
糖尿病视网膜病变(diabetic retinopathy，DR)是糖尿病最常见、最典型的微血管并发症之一，也是我国成人失明或严重视力丧失的主要原因。目前关于DR的治疗主要包括药物治疗、激光治疗以及手术治疗，但这些治疗多为侵入性、破坏性的治疗，且不良反应多，因此寻找新的治疗靶点成为防治DR的热点。微小RNA(microRAN，miRNA)是理想的生物标志物，在细胞凋亡、炎症、氧化应激、病理性新生血管的形成中起到重要的调控作用，有望成为治疗DR的生物学标志物，文章总结了miRNA在DR治疗中的最新研究进展，为DR的临床防治提供新的思路。 Diabetic retinopathy (DR) is one of the most common and typical microvascular complications of diabetes mellitus, and it is also the main cause of blindness or severe visual loss in adults in China. At present, the treatment of DR mainly includes drug therapy, laser therapy and surgical treatment, but most of these treatments are invasive and destructive, and have many adverse reactions. Therefore, finding new therapeutic targets has become a hot spot in the prevention and treatment of DR. MicroRNA(miRNA) is an ideal biomarker, which plays an important regulatory role in apoptosis, inflammation, oxidative stress and pathological neovascularization, and is expected to become a biomarker for the treatment of DR. This article summarizes the latest research progress of miRNA in the treatment of DR, and provides new ideas for the clinical prevention and treatment of DR.
Diabetic retinopathy (DR) is one of the most common and typical microvascular complications of diabetes mellitus, and it is also the main cause of blindness or severe visual loss in adults in China. At present, the treatment of DR mainly includes drug therapy, laser therapy and surgical treatment, but most of these treatments are invasive and destructive, and have many adverse reactions. Therefore, finding new therapeutic targets has become a hot spot in the prevention and treatment of DR. MicroRNA(miRNA) is an ideal biomarker, which plays an important regulatory role in apoptosis, inflammation, oxidative stress and pathological neovascularization, and is expected to become a biomarker for the treatment of DR. This article summarizes the latest research progress of miRNA in the treatment of DR, and provides new ideas for the clinical prevention and treatment of DR.

Diabetes retinopathyMiRNAChronic inflammationOxidative stressImmune responseTargeted therapy

王昌琴、吕洋

展开 >

甘肃省中医药大学第一临床医学院，兰州　730000

2中国人民解放军联勤保障部队第九四○医院眼科中心，兰州　730000

中国人民解放军联勤保障部队第九四○医院眼科中心，兰州　730000

糖尿病性视网膜病变 miRNA 慢性炎症 氧化应激 免疫反应 靶向治疗

国家自然科学基金甘肃省卫生健康委员基金联勤保障部队第九四〇医院院项目联勤保障部队第九四〇医院院项目联勤保障部队第九四〇医院院项目

82000926GSWSKY2022-052021yxky0332023YXKYO112023YXKY033

2024

10.3760/cma.j.issn.1673-4394.2024.02.013

国际免疫学杂志
中华医学会 哈尔滨医科大学

国际免疫学杂志

CSTPCD
影响因子：0.774
ISSN：1673-4394
年,卷(期)：2024.47(2)
  • 38